FMO7P

Across TCGA pan-cancer cohorts, FMO7P RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of FMO7P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FMO7P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FMO7P is over-expressed in tumor.

KIRC, KIRP, and COAD are the cancer types where FMO7P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FMO7P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.097	<.001	11	view →
KIRP	All	II,III,IV	+0.058	.009	8	view →
COAD	All	All	+0.111	<.001	6	view →
BRCA	All	All	+0.040	.004	4	view →
STAD	All	All	+0.062	.008	3	view →
HNSC	All	All	+0.023	.010	3	view →
LIHC	All	All	+0.112	.003	2	view →
LUAD	All	All	+0.043	.026	2	view →
LUSC	All	All	+0.028	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

FMO7P–KIRC

Open the KIRC breakdown →